Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
19661353
PII: 29/8/3337
Knihovny.cz E-resources
- MeSH
- alpha-Tocopherol blood MeSH
- C-Reactive Protein metabolism MeSH
- Fibrinogen metabolism MeSH
- Antineoplastic Agents, Hormonal pharmacology MeSH
- Aromatase Inhibitors pharmacology MeSH
- Humans MeSH
- Lipoprotein(a) metabolism MeSH
- Lipoproteins, LDL metabolism MeSH
- Lipoproteins, VLDL metabolism MeSH
- Breast Neoplasms drug therapy metabolism pathology MeSH
- Neopterin urine MeSH
- Prognosis MeSH
- Prospective Studies MeSH
- Tamoxifen pharmacology MeSH
- Vitamin A blood MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- alpha-Tocopherol MeSH
- C-Reactive Protein MeSH
- Fibrinogen MeSH
- Antineoplastic Agents, Hormonal MeSH
- Aromatase Inhibitors MeSH
- Lipoprotein(a) MeSH
- Lipoproteins, LDL MeSH
- Lipoproteins, VLDL MeSH
- Neopterin MeSH
- Tamoxifen MeSH
- Vitamin A MeSH
BACKGROUND: Aromatase inhibitors may affect lipid metabolism, inflammatory response and antioxidant balance. PATIENTS AND METHODS: One hundred and eighty-six post-menopausal patients with breast carcinoma underwent evaluation of parameters of lipid metabolism, inflammatory response and antioxidant balance immediately before as well as 2 and 4 months after the start of therapy with aromatase inhibitors. RESULTS: A significant increase in total, very low density lipoprotein (VLDL) and low density lipoprotein (LDL) cholesterol, lipoprotein (a), retinol, C-reactive protein and fibrinogen was observed. The changes of serum lipid concentrations were restricted mostly to the patients pre-treated with tamoxifen who had significantly lower baseline levels of these parameters. CONCLUSION: An increase of serum cholesterol, lipoprotein (a), C-reactive protein and fibrinogen in patients treated with aromatase inhibitors is the result of tamoxifen withdrawal rather than a direct effect of therapy. No significant changes in serum lipids were observed in patients treated with aromatase inhibitors in the first-line setting.
